Clinical trial
Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated)…
NCT00191724 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191724 |
|---|---|
| Title | Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study |
| Official title | Drotrecogin Alfa (Activated) (LY203638)] Exploratory, Safety Study, Multi-Center, Randomized, Placebo-Controlled, Dose Escalating Study Design, Comparing a Standard Therapy (Enoxaparin Sodium) for Submassive Pulmonary Embolism to a Combined Therapy of Drotrecogin Alfa (Activated) Plus Enoxaparin… |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Submassive Pulmonary Embolism |
| Intervention type | Drug |
| Interventions | Drotrecogin Alfa (Activated), Enoxaparin, Placebo |
| Enrollment | 47 |
| Start date | Sep 1, 2004 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Jun 24, 2009 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: